119 related articles for article (PubMed ID: 23895151)
1. The efficacy and safety of standardized allergen-removed Rhus verniciflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung cancer.
Lee J; Chae J; Lee S; Kim K; Eo W; Kim S; Choi W; Cheon SH
Am J Chin Med; 2013; 41(4):773-87. PubMed ID: 23895151
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Rhus verniciflua stokes extracts in patients with previously treated advanced non-small cell lung cancer.
Cheon SH; Kim KS; Kim S; Jung HS; Choi WC; Eo WK
Forsch Komplementmed; 2011; 18(2):77-83. PubMed ID: 21576976
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience.
Lee S; Kim K; Jung H; Lee S; Cheon S; Kim S; Eo W; Choi W
Oncology; 2011; 81(5-6):312-8. PubMed ID: 22179506
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
5. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
[TBL] [Abstract][Full Text] [Related]
6. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
7. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
Giaccone G; Bazhenova LA; Nemunaitis J; Tan M; Juhász E; Ramlau R; van den Heuvel MM; Lal R; Kloecker GH; Eaton KD; Chu Q; Dunlop DJ; Jain M; Garon EB; Davis CS; Carrier E; Moses SC; Shawler DL; Fakhrai H
Eur J Cancer; 2015 Nov; 51(16):2321-9. PubMed ID: 26283035
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
9. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
Zhou C; Wu Y; Sun Y; Wang Y; Wang X; Zhang X
Zhonghua Zhong Liu Za Zhi; 2014 Jan; 36(1):29-33. PubMed ID: 24685083
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
13. Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC).
Nørøxe DS; Wallerek S; Sørensen JB
Anticancer Res; 2013 Aug; 33(8):3275-8. PubMed ID: 23898091
[TBL] [Abstract][Full Text] [Related]
14. Maintenance chemotherapy in advanced NSCLC: a population-based assessment of eligibility.
Tong KM; Laskin J; Ho C
Lung Cancer; 2015 Mar; 87(3):296-302. PubMed ID: 25601487
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Wang Z; Zhu XX; Wu XH; Li B; Shen TZ; Kong QT; Li J; Liu ZB; Jiang WR; Wang Y; Hou B
Am J Clin Oncol; 2014 Apr; 37(2):148-53. PubMed ID: 23211223
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
17. Third-line therapy in advanced non-small cell lung cancer.
Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
[TBL] [Abstract][Full Text] [Related]
18. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
Zheng X; Wang H; Zhang G; Yan X; Ma Z
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):513-518. PubMed ID: 30037370
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis.
Lopez-Chavez A; Young T; Fages S; Leon L; Schiller JH; Dowlati A; Brahmer JR; Johnson DH; Sandler A
J Thorac Oncol; 2012 Nov; 7(11):1707-12. PubMed ID: 23059774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
